U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
149124
Substance Class Protein
Created
by admin
on Mon Mar 31 22:23:30 GMT 2025
Edited
by admin
on Mon Mar 31 22:23:30 GMT 2025
Protein Sub Type
Sequence Type COMPLETE
Record UNII
ZWJ2Y6JZWY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OAT-3
Common Name English
MGC24086
Preferred Name English
OAT3
Common Name English
ORGANIC ANION TRANSPORTER 3
Common Name English
SLC22A8
Common Name English
SOLUTE CARRIER FAMILY 22 MEMBER 8
Common Name English
Classification Tree Code System Code
UCSF-FDA TRANSPORTAL SLC22A8
Created by admin on Mon Mar 31 22:23:30 GMT 2025 , Edited by admin on Mon Mar 31 22:23:30 GMT 2025
Code System Code Type Description
FDA UNII
ZWJ2Y6JZWY
Created by admin on Mon Mar 31 22:23:30 GMT 2025 , Edited by admin on Mon Mar 31 22:23:30 GMT 2025
PRIMARY
UNIPROT
Q8TCC7
Created by admin on Mon Mar 31 22:23:30 GMT 2025 , Edited by admin on Mon Mar 31 22:23:30 GMT 2025
PRIMARY
Glycosylation Type HUMAN
Glycosylation Link Type Site
N 1_86
N 1_102
Related Record Type Details
Structure of CITRININ
INHIBITOR -> TRANSPORTER
Structure of ACETAZOLAMIDE
INHIBITOR -> TRANSPORTER
Structure of PANOBINOSTAT
INHIBITOR -> TRANSPORTER
Structure of FEVIPIPRANT
SUBSTRATE -> TRANSPORTER
Structure of OLMESARTAN
INHIBITOR -> TRANSPORTER
Structure of LESINURAD
INHIBITOR -> TRANSPORTER
Based on in vitro studies, lesinurad is a weak inhibitor of OATP1B1, OCT1, OAT1, and OAT3.
WEAK
Structure of FLUVASTATIN
INHIBITOR -> TRANSPORTER
Structure of CEPHALOTHIN
INHIBITOR -> TRANSPORTER
Structure of NAPROXEN
INHIBITOR -> TRANSPORTER
Structure of IBUPROFEN
INHIBITOR -> TRANSPORTER
Structure of PEMETREXED
SUBSTRATE -> TRANSPORTER
Structure of CEFOPERAZONE
INHIBITOR -> TRANSPORTER
Structure of INDOMETHACIN
INHIBITOR -> TRANSPORTER
Structure of CIDOFOVIR ANHYDROUS
SUBSTRATE -> TRANSPORTER
Structure of CABOTEGRAVIR
INHIBITOR -> TRANSPORTER
IN VITRO
IC50
Structure of PIROXICAM
INHIBITOR -> TRANSPORTER
Structure of ERLOTINIB
SUBSTRATE -> TRANSPORTER
Structure of ELISMETREP
INHIBITOR -> TRANSPORTER
Structure of BMS-986224
INHIBITOR -> TRANSPORTER
Structure of ARTESUNATE
INHIBITOR -> TRANSPORTER
WEAK
Structure of Perampanel
INHIBITOR -> TRANSPORTER
Thus, the unbound Cmax is about 0.09 ?M, much lower than 8.5 ?M. Therefore, E2007 is unlikely to inhibit OAT1, OAT3, OCT1 and OCT3 in vivo.
Ki
Structure of CEFOTAXIME
INHIBITOR -> TRANSPORTER
Structure of TAFAMIDIS
INHIBITOR -> TRANSPORTER
IC50
Structure of INDAPAMIDE
INHIBITOR -> TRANSPORTER
Structure of ETHACRYNIC ACID
INHIBITOR -> TRANSPORTER
Structure of PROBENECID
INHIBITOR -> TARGET
Structure of CHLOROTHIAZIDE
INHIBITOR -> TRANSPORTER
Structure of CILASTATIN
INHIBITOR -> TRANSPORTER
Structure of AVATROMBOPAG
INHIBITOR -> TRANSPORTER
IC50
Structure of ABAMETAPIR
INHIBITOR -> TRANSPORTER
but the ratio of the unbound Cmax to the IC50 is less than 0.1
IC50
Structure of 1-(((4-((7-METHOXY-6-(SULFOOXY)-4-QUINOLINYL)OXY)PHENYL)AMINO)CARBONYL)CYCLOPROPANECARBOXYLIC ACID
SUBSTRATE -> TRANSPORTER
Structure of PHENACETIN
INHIBITOR -> TRANSPORTER
Structure of ELUXADOLINE
SUBSTRATE -> TRANSPORTER
Structure of Zagociguat
INHIBITOR -> TRANSPORTER
IC50
Structure of EDARAVONE
SUBSTRATE -> TRANSPORTER
Structure of TELMISARTAN
INHIBITOR -> TRANSPORTER
Structure of PRETOMANID
INHIBITOR -> TRANSPORTER
In vitro studies indicate that pretomanid significantly inhibits the OAT3 drug transporter which could result in increased concentrations of OAT3 substrates at clinically relevant concentrations of pretomanid. No clinical DDI studies have been conducted with OAT3 substrates.
Structure of DOTINURAD
INHIBITOR -> TRANSPORTER
IC50
Structure of NOVOBIOCIN
INHIBITOR -> TRANSPORTER
Structure of EDARAVONE
INHIBITOR -> TRANSPORTER
Edaravone inhib it e d CYP2C9, BCRP, OAT3, and induced CYP1A2 in vitro.
Structure of IPTACOPAN
NON-SUBSTRATE -> TRANSPORTER
Structure of BARICITINIB
SUBSTRATE -> TRANSPORTER
Structure of EPAMINURAD
INHIBITOR->OFF-TARGET
Structure of Teriflunomide
INHIBITOR -> TRANSPORTER
Terifluniomide is an inhibitor of BCRP, OAT3, OATP1B1, OCT2 in vitro
Structure of METHOTREXATE
SUBSTRATE -> TRANSPORTER
Structure of GEMFIBROZIL 1-O-.BETA.-GLUCURONIDE
INHIBITOR -> TRANSPORTER
Structure of CEFTRIAXONE
INHIBITOR -> TRANSPORTER
Structure of MEFENAMIC ACID
INHIBITOR -> TRANSPORTER
Structure of Selexipag
INHIBITOR -> TRANSPORTER
IC50
Structure of SIMVASTATIN
INHIBITOR -> TRANSPORTER
Structure of GEMFIBROZIL
INHIBITOR -> TRANSPORTER
Structure of Olaparib
INHIBITOR -> TRANSPORTER
Structure of TRICHLORMETHIAZIDE
INHIBITOR -> TRANSPORTER
Structure of VALSARTAN
INHIBITOR -> TRANSPORTER
Structure of PRAVASTATIN
INHIBITOR -> TRANSPORTER
Structure of Laselipag
INHIBITOR -> TRANSPORTER
IC50
Structure of CEPHALORIDINE
INHIBITOR -> TRANSPORTER
Structure of SULINDAC
INHIBITOR -> TRANSPORTER
Structure of PROBENECID
INHIBITOR -> TRANSPORTER
Structure of Bumetanide
INHIBITOR -> TRANSPORTER
Structure of BENZNIDAZOLE
INHIBITOR -> TRANSPORTER
IC50
Structure of MEROPENEM
SUBSTRATE -> TRANSPORTER
Structure of CENOBAMATE
INHIBITOR -> TRANSPORTER
WEAK
Structure of Sulfasalazine
INHIBITOR -> TRANSPORTER
Structure of OPICAPONE
INHIBITOR -> TRANSPORTER
IC50
Structure of BETAMIPRON
INHIBITOR -> TRANSPORTER
ALBUMIN BOVINE
INHIBITOR -> TRANSPORTER
Structure of TENOFOVIR ANHYDROUS
SUBSTRATE -> TRANSPORTER
Structure of HYDROCHLOROTHIAZIDE
INHIBITOR -> TRANSPORTER
Structure of NPT520-34
INHIBITOR -> TARGET
Structure of ABROCITINIB METABOLITE M1
SUBSTRATE -> TRANSPORTER
Structure of Losartan
INHIBITOR -> TRANSPORTER
Structure of RESVERATROL
INHIBITOR -> TRANSPORTER
MTX uptake was markedly inhibited by Res in rat kidney slicesand hOAT1/3-HEK293 cell, indicating that OAT1 and OAT3 were involved in the drug interaction in the kidney
Structure of CANDESARTAN
INHIBITOR -> TRANSPORTER
Structure of LORLATINIB
INHIBITOR -> TRANSPORTER
Structure of Resmetirom
INHIBITOR -> TRANSPORTER
clinical relevance of inhibition is unknown
Structure of 1-(((4-((7-METHOXY-6-(SULFOOXY)-4-QUINOLINYL)OXY)PHENYL)AMINO)CARBONYL)CYCLOPROPANECARBOXYLIC ACID
INHIBITOR -> TRANSPORTER
IC50
Structure of BRANEBRUTINIB
INHIBITOR -> TRANSPORTER
Structure of METHAZOLAMIDE
INHIBITOR -> TRANSPORTER
Structure of CIMETIDINE
INHIBITOR -> TRANSPORTER
Structure of CEFADROXIL
INHIBITOR -> TRANSPORTER
Structure of ABROCITINIB METABOLITE M2
SUBSTRATE -> TRANSPORTER
Structure of PENICILLIN G
INHIBITOR -> TRANSPORTER
Structure of QUINAPRIL
INHIBITOR -> TRANSPORTER
Structure of IMATINIB
SUBSTRATE -> TRANSPORTER
Structure of Rifamycin
INHIBITOR -> TRANSPORTER
Rifamycin is an inhibitor of renal transporters organic anion transporter (OAT) 3, multidrug and toxin extrusion (MATE) 1, and MATE2-K transporters in vitro, however, based on systemic concentrations of rifamycin observed after administration of the recommended dose, clinically relevant inhibition of these transporters in vivo is unlikely.
Structure of LESINURAD
SUBSTRATE -> TRANSPORTER
Based on in vitro studies, lesinurad is a substrate of OAT1 and OAT3.
Structure of ZIDOVUDINE
SUBSTRATE -> TRANSPORTER
Structure of Apalutamide
INHIBITOR -> TRANSPORTER
Structure of ABAMETAPIR CARBOXYL
INHIBITOR -> TRANSPORTER
IC50
Structure of CYCLOTHIAZIDE
INHIBITOR -> TRANSPORTER
Structure of Sitagliptin
INHIBITOR -> TRANSPORTER
Structure of ABROCITINIB
INHIBITOR -> TRANSPORTER
Structure of Acetylcysteine
SUBSTRATE -> TRANSPORTER
Structure of DICLOFENAC
INHIBITOR -> TRANSPORTER
Structure of KETOPROFEN
INHIBITOR -> TRANSPORTER
Structure of CEFAMANDOLE
INHIBITOR -> TRANSPORTER
Structure of ENCORAFENIB
INHIBITOR -> TRANSPORTER
IC50
Structure of PRATOSARTAN
INHIBITOR -> TRANSPORTER
Structure of FENOFIBRIC ACID
INHIBITOR -> TRANSPORTER
Structure of CIMETIDINE
SUBSTRATE -> TRANSPORTER
Structure of FUROSEMIDE
INHIBITOR -> TRANSPORTER
Structure of FAMOTIDINE
NON-INHIBITOR -> TRANSPORTER
Structure of RELEBACTAM ANHYDROUS
SUBSTRATE -> TRANSPORTER
in vitro
Structure of CEFAZOLIN
INHIBITOR -> TRANSPORTER
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966